Oncology

Useful For Assessing the patient’s probability of having detectable prostate cancer when total prostate specific antigen (PSA) concentrations are between 4–10 ng/mL. Results from a[...]

Some early-stage cancers are missed by conventional screening and are only detected when symptoms occur. Mayo Clinic is collaborating with Grail, a life science company, and Sutter Health of California, on the STRIVE clinical research study to facilitate the development of Grail’s blood tests for early-stage cancer detection.

This week’s Research Roundup highlights the best tumor size cut-points for renal cell carcinoma staging.

This week’s Research Roundup highlights how AKT-phosphorylated FOXO1 suppresses ERK activation and chemoresistance by disrupting IQGAP1-MAPK interaction.